ADIAL PHARMACEUTICALS, INC. current report, 23 February 2023

Full document

Business Context and Reporting Period

Company: Adial Pharmaceuticals, Inc. (ADIL)
Filing Type: Form 8-K (Current Report)
Date of Report: February 23, 2023
Event: Entry into a Material Definitive Agreement for a registered direct offering of common stock.

Key Financial Metrics

This filing reports on a specific capital raise transaction rather than periodic financial performance. Key transaction metrics include:

  • Shares Issued: 1,829,269 shares of Common Stock.
  • Aggregate Purchase Price: Approximately $750,000.
  • Estimated Net Proceeds: Approximately $550,000 (after fees and expenses).
  • Use of Proceeds: Working capital purposes.
  • Placement Agent Fee: 10% of the aggregate purchase price plus expenses not to exceed $35,000.
  • Placement Agent Warrants: 182,927 warrants (10% of shares sold) with an exercise price of $0.41.

Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transactional report, not a financial statement.

Material Changes

The primary material change is the execution of a Securities Purchase Agreement with an accredited institutional investor. This transaction results in the immediate issuance of new equity and warrants, altering the company's capital structure and cash position upon closing.

Guidance, Outlook, and Risks

  • Closing Date: Expected on or about February 24, 2023, subject to customary conditions.
  • Voting Agreement: The Investor agreed to vote all beneficially owned shares on proposals presented at the next stockholder meeting, though they are not bound to vote for or against specific proposals.
  • Warrant Terms: Placement Agent Warrants are exercisable two months after closing, expire in five years, and include cashless exercise provisions and anti-dilution protection (excluding price protection).
  • Risks: The Placement Agent has no obligation to purchase shares or arrange for a specific dollar amount of sales.

Investor Verification Checklist

  • Verify the final closing date and actual net proceeds received.
  • Confirm the exact number of shares outstanding post-issuance to assess dilution impact.
  • Review the full text of the Voting Agreement (Exhibit 10.3) for specific voting obligations.
  • Monitor the exercise of Placement Agent Warrants (182,927 shares) at the $0.41 strike price.
  • Check subsequent filings for the utilization of the $550,000 net proceeds for working capital.